Mechanism of action
Cannabidiol's precise anticonvulsant mechanism remains incompletely understood, but it modulates multiple CNS targets without significant affinity for classical cannabinoid CB1 or CB2 receptors, distinguishing it from THC.
Primary proposed mechanisms include:
- Voltage-gated sodium channel modulation: CBD may inhibit persistent sodium currents, reducing neuronal hyperexcitability similar to traditional anticonvulsants
- GPR55 antagonism: Blockade of this orphan G-protein coupled receptor may contribute to anticonvulsant effects
- TRPV1 activation: Transient receptor potential vanilloid 1 channel agonism may modulate calcium homeostasis
- Adenosine reuptake inhibition: Enhanced adenosine signaling provides anti-inflammatory and neuroprotective effects
- 5-HT1A receptor agonism: Serotonergic activity may contribute to anxiolytic and anticonvulsant properties
- GABA modulation: Positive allosteric modulation of GABA-A receptors enhances inhibitory neurotransmission
CBD also exhibits anti-inflammatory properties through modulation of cytokine release and oxidative stress pathways. The lack of CB1 receptor agonism explains the absence of psychoactive effects, cognitive impairment, and abuse potential seen with THC. The multi-target mechanism may explain efficacy in treatment-resistant epilepsies where single-target agents fail.
- Cannabidiol is FDA-approved for Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex seizures in patients ≥1 year
- CBD does not bind CB1 receptors, lacks psychoactive effects, and has minimal abuse potential; FDA-approved CBD is not a controlled substance
- Hepatotoxicity is the most serious adverse effect; risk increases with valproate co-administration; LFT monitoring mandatory
- CBD inhibits CYP2C19, increasing clobazam's active metabolite by up to 3-fold; clobazam dose reduction often needed
- Bioavailability increases 4-5 fold when taken with high-fat meals; advise consistent administration
- Unlike THC, CBD does not cause euphoria, dependence, or cognitive impairment
- Over-the-counter CBD products are not FDA-approved and lack standardized quality or potency
- Long half-life of 56-61 hours means steady state achieved after approximately 2 weeks of dosing
Indications
FDA-approved indications:
- Dravet syndrome: Severe myoclonic epilepsy of infancy, typically due to SCN1A mutations, in patients ≥1 year old
- Lennox-Gastaut syndrome: Childhood-onset epileptic encephalopathy with multiple seizure types, in patients ≥1 year old
- Tuberous sclerosis complex (TSC)-associated seizures: In patients ≥1 year old
CBD is approved as adjunctive therapy alongside other antiepileptic drugs for these treatment-resistant epilepsy syndromes. Clinical trials demonstrated significant reductions in seizure frequency compared to placebo, with some patients achieving seizure freedom.
Off-label and investigational uses (not FDA-approved, evidence variable):
- Anxiety disorders
- Chronic pain syndromes
- Post-traumatic stress disorder
- Substance use disorders
- Movement disorders
Prescribers should note that over-the-counter CBD products are not FDA-approved medications and lack standardized quality, purity, and dosing. Only pharmaceutical-grade CBD (Epidiolex in the US) has undergone rigorous clinical trials and quality control.
Pharmacokinetics
Absorption: Oral bioavailability is low (approximately 6% on empty stomach) but increases significantly when taken with high-fat meals (up to 4-5 fold). Peak plasma concentrations occur 2.5-5 hours post-dose.
Distribution: CBD is highly lipophilic with extensive tissue distribution. Volume of distribution ranges from 20,000-30,000 L following chronic dosing. Plasma protein binding exceeds 94%. CBD crosses the blood-brain barrier and achieves therapeutic CNS concentrations.
Metabolism: Extensive hepatic metabolism primarily via CYP3A4 and CYP2C19, with minor contributions from CYP1A2, CYP2C9, and CYP2D6. The major active metabolite is 7-hydroxy-CBD, which contributes to clinical effects. First-pass metabolism is substantial, contributing to low oral bioavailability.
Excretion: Predominantly fecal elimination (>80%) with minimal renal excretion. The elimination half-life is approximately 56-61 hours following chronic twice-daily dosing, allowing for steady-state achievement within 7-10 days.
Special populations: Hepatic impairment significantly increases CBD exposure (dose reduction required). Renal impairment does not meaningfully alter pharmacokinetics. Pediatric patients (1-17 years) show similar pharmacokinetics to adults when adjusted for body weight.
Adverse effects
Common adverse effects (>10% incidence):
- Somnolence and sedation (most common, dose-related)
- Decreased appetite and weight loss
- Diarrhea
- Fatigue and malaise
- Elevated liver transaminases (AST/ALT)
- Insomnia
- Rash
Serious adverse effects:
Hepatotoxicity: Dose-dependent transaminase elevations occur in up to 30% of patients, particularly when co-administered with valproate. This is a major Warning and Precaution for hepatocellular injury. Baseline liver function tests required, with regular monitoring during treatment. Discontinuation may be necessary if ALT/AST exceed 3× upper limit of normal with hyperbilirubinemia, or 5× upper limit without hyperbilirubinemia.
Drug-induced liver injury: Cases of severe hepatotoxicity requiring transplantation have been reported, though rare.
Hematologic effects: Anemia, lymphopenia, and thrombocytopenia may occur.
Hypersensitivity reactions: Rare cases of angioedema, urticaria, and anaphylaxis reported.
Suicidal ideation and behavior: All antiepileptic drugs carry this risk; patients and caregivers should be counseled.
Other notable effects:
- Infections (increased susceptibility, particularly upper respiratory)
- Behavioral changes, aggression, agitation
- Depression
- Sedation potentiation with other CNS depressants
Adverse effects are generally dose-related and may improve with dose reduction. Unlike THC, CBD does not cause euphoria, cognitive impairment, or physiologic dependence.
Contraindications and warnings
Absolute contraindications:
- Hypersensitivity to cannabidiol or any formulation component (including sesame oil in some products)
Warnings and precautions:
Hepatotoxicity: The most significant safety concern. Baseline and periodic liver function monitoring mandatory (monthly for first 3 months, then periodically). Risk increases with concomitant valproate use. Dose reduction or discontinuation required based on transaminase elevations and bilirubin.
Drug interactions: CBD is both a substrate and inhibitor of multiple CYP enzymes (see Drug Interactions section). Concurrent use with CYP3A4 or CYP2C19 inhibitors/inducers requires dose adjustment. Particular caution with clobazam, as CBD significantly increases levels of the active N-desmethylclobazam metabolite.
Pregnancy and lactation: Pregnancy category not formally assigned (FDA abandoned letter categories). Animal studies show developmental toxicity at clinically relevant exposures. CBD should be used during pregnancy only if potential benefit justifies fetal risk. CBD and metabolites are excreted in breast milk; breastfeeding not recommended.
Somnolence and sedation: Additive effects with other CNS depressants (benzodiazepines, opioids, alcohol, barbiturates). Counsel patients about activities requiring alertness (driving, operating machinery).
Suicidal behavior and ideation: Standard antiepileptic drug warning applies. Monitor for emergence or worsening of depression, suicidal thoughts, or unusual behavior changes.
Withdrawal: Abrupt discontinuation may increase seizure frequency. Gradual tapering recommended if discontinuation necessary.
Controlled substance status: FDA-approved pharmaceutical cannabidiol (Epidiolex) was fully descheduled by the DEA in April 2020 and is no longer a federally controlled substance. This reflects its lack of abuse potential and distinguishes it from THC-containing products.
Drug interactions
CBD participates in significant pharmacokinetic drug interactions through CYP enzyme inhibition and induction.
Major interactions requiring dose adjustment:
Clobazam: CBD inhibits CYP2C19, dramatically increasing levels of the active metabolite N-desmethylclobazam (up to 3-fold). This potentiates sedation and may require clobazam dose reduction by 50% or more. Monitor for excessive sedation and consider therapeutic drug monitoring.
Valproate/valproic acid: Co-administration substantially increases hepatotoxicity risk. Up to 30% of patients on combination therapy develop transaminase elevations versus 10-15% on CBD monotherapy. More frequent liver function monitoring required. Consider alternative antiepileptic if possible.
CYP3A4 and CYP2C19 substrates: CBD inhibits these enzymes at therapeutic doses. May increase levels of:
- Benzodiazepines (midazolam, triazolam)
- Calcium channel blockers
- Immunosuppressants (tacrolimus, cyclosporine)
- Macrolide antibiotics
- Statins
- Warfarin (monitor INR)
CYP3A4 and CYP2C19 inhibitors: Increase CBD exposure. Examples:
- Azole antifungals (ketoconazole, itraconazole)
- Protease inhibitors
- Grapefruit juice
CBD dose reduction may be necessary.
CYP3A4 and CYP2C19 inducers: Decrease CBD exposure, potentially reducing efficacy. Examples:
- Rifampin
- Carbamazepine
- Phenytoin
- Phenobarbital
- St. John's wort
CBD dose increase may be necessary.
CNS depressants: Additive sedation with alcohol, benzodiazepines, opioids, barbiturates, sedating antihistamines, and other antiepileptic drugs.
Other antiepileptic drugs: Beyond specific interactions noted, many AEDs have overlapping toxicity profiles (sedation, hepatotoxicity). Monitor closely when adding CBD to existing regimens.
Alcohol: Additive CNS depression. Patients should avoid alcohol consumption.
Therapeutic drug monitoring may be helpful for drugs with narrow therapeutic indices when initiating or adjusting CBD therapy.
Clinical pearls
High-yield examination points:
- CBD is the first FDA-approved cannabis-derived pharmaceutical for any indication (2018 approval for Dravet and Lennox-Gastaut syndromes)
- Unlike THC, CBD does not bind CB1 receptors and therefore lacks psychoactive effects, euphoria, or abuse potential
- The most important adverse effect is hepatotoxicity, particularly when combined with valproate; baseline and periodic LFT monitoring is mandatory
- CBD dramatically increases clobazam levels through CYP2C19 inhibition, often necessitating dose reduction
- Administration with high-fat meals increases bioavailability 4-5 fold; counsel patients on consistent administration with respect to meals
- FDA-approved pharmaceutical cannabidiol (Epidiolex) was descheduled by the DEA in 2020 and is not a controlled substance, reflecting minimal abuse potential
Clinical practice tips:
- Start with lower doses and titrate gradually based on seizure response and tolerability
- When adding CBD to existing antiepileptic regimens, anticipate need for dose adjustments of other medications, particularly clobazam and valproate
- Over-the-counter CBD products are not FDA-approved medications and have variable quality, potency, and contamination; they should not be considered therapeutically equivalent to pharmaceutical CBD
- Patients may experience sedation, particularly during titration; warn about impaired driving and operating machinery
- CBD has a long half-life (56-61 hours); steady state takes approximately 2 weeks to achieve
- Cost can be a barrier; pharmaceutical CBD is expensive, and insurance coverage varies
Monitoring recommendations:
- Liver function tests: baseline, at 1 month, 3 months, 6 months, then periodically; more frequently if on valproate
- Complete blood count periodically (monitor for anemia, thrombocytopenia)
- Seizure frequency documentation
- Mental health screening (depression, suicidal ideation)
- Weight and growth in pediatric patients
Patient counseling:
- Take consistently with or without food (with high-fat meals increases absorption)
- Report signs of liver injury: nausea, vomiting, right upper quadrant pain, fatigue, anorexia, jaundice, dark urine
- Report worsening mood, depression, or suicidal thoughts
- Do not stop abruptly (seizure risk)
- Avoid alcohol and limit other CNS depressants
- CBD does not produce a "high" like marijuana
Practice questions
1. A 4-year-old girl with Dravet syndrome continues to have multiple seizures daily despite treatment with valproate and clobazam. Her neurologist adds cannabidiol to her regimen. Two weeks later, her mother reports increased drowsiness. Laboratory studies show AST 185 U/L (normal <40) and ALT 210 U/L (normal <40). Which medication interaction most likely accounts for the clinical findings of drowsiness?
2. A 28-year-old man with treatment-resistant epilepsy asks his physician about using CBD oil purchased online to help control his seizures. He states the product is "natural" and "legal" so it should be safe. Which of the following is the most appropriate response?
3. A 6-year-old boy with Lennox-Gastaut syndrome is started on cannabidiol in addition to his current antiepileptic regimen. His mother is counseled about potential adverse effects. At his 1-month follow-up, which laboratory test is most important to monitor?
Frequently asked questions
How does cannabidiol (CBD) work?
Cannabidiol works through multiple mechanisms in the brain, including modulation of voltage-gated sodium channels, GPR55 antagonism, and enhancement of GABA signaling. Unlike THC, CBD does not bind to CB1 cannabinoid receptors, which explains why it lacks psychoactive effects. The precise mechanism of its anticonvulsant action is not fully understood, but the multi-target approach may explain its effectiveness in treatment-resistant epilepsy syndromes where single-mechanism drugs fail.
What are the side effects of cannabidiol?
The most common side effects are drowsiness, decreased appetite, diarrhea, and fatigue. The most serious adverse effect is hepatotoxicity (liver damage), which occurs more frequently when CBD is combined with valproate. This requires regular monitoring of liver function tests. Other important side effects include elevated liver enzymes, infections, rash, anemia, and potential for suicidal thoughts (as with all antiepileptic drugs). Unlike THC-containing cannabis, CBD does not cause euphoria, cognitive impairment, or dependence.
Is cannabidiol (CBD) a controlled substance?
No, FDA-approved pharmaceutical cannabidiol (Epidiolex) was fully descheduled by the DEA in April 2020 and is no longer a federally controlled substance. This reflects that CBD has accepted medical use and minimal risk of physical or psychological dependence. This descheduling applies to FDA-approved CBD medications; over-the-counter CBD products occupy a complex legal gray area. The descheduled status distinguishes pharmaceutical CBD from THC and marijuana, which remain Schedule I substances.
Cannabidiol vs THC — what is the difference?
Cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) are both cannabinoids from Cannabis sativa but have fundamentally different effects. THC binds strongly to CB1 receptors in the brain, producing euphoria, altered perception, and cognitive impairment, while CBD does not bind CB1 receptors and lacks psychoactive effects. CBD is FDA-approved for epilepsy treatment and has no abuse potential (not a controlled substance), whereas THC remains federally illegal (Schedule I) despite state-level legalization. CBD does not cause dependence or withdrawal, while THC can lead to cannabis use disorder in susceptible individuals.
Can you take cannabidiol with other seizure medications?
Yes, cannabidiol is specifically approved as adjunctive therapy, meaning it is used alongside other antiepileptic drugs. However, important drug interactions require careful management. CBD significantly increases clobazam levels, often requiring dose reduction of clobazam. Combination with valproate substantially increases the risk of liver toxicity, necessitating more frequent liver function monitoring. CBD also interacts with medications metabolized by CYP3A4 and CYP2C19 enzymes. Always inform your healthcare provider of all medications you are taking before starting CBD, and never adjust doses without medical supervision.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: N03AX24
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.